Literature DB >> 12010611

Update on colchicine and its mechanism of action.

Yair Molad1.   

Abstract

Colchicine is a unique anti-inflammatory drug with respect to its limited clinical usefulness and its mode of action. Colchicine is mainly indicated for the treatment and prophylaxis of gout and familial Mediterranean fever. Its mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules by which it interferes with the initiation and amplification of the joint inflammation. This paper discusses its adverse effects and indications.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12010611     DOI： 10.1007/s11926-002-0073-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  49 in total

Review 1.  Role of microtubules in the phasic pattern of insulin release.

Authors:  W J Malaisse; F Malaisse-Lagae; E Van Obberghen; G Somers; G Devis; M Ravazzola; L Orci
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

2.  Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules.

Authors:  A Vandecandelaere; S R Martin; Y Engelborghs
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

3.  Histamine release from rat peritoneal mast cells: inhibition by colchicine and potentiation by deuterium oxide.

Authors:  E Gillespie; R J Levine; S E Malawista
Journal:  J Pharmacol Exp Ther       Date:  1968-11       Impact factor: 4.030

4.  Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylate.

Authors:  D G Wright; S E Malawista
Journal:  Arthritis Rheum       Date:  1973 Nov-Dec

Review 5.  The management of gout.

Authors:  B T Emmerson
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

6.  Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.

Authors:  M Rochdi; A Sabouraud; C Girre; R Venet; J M Scherrmann
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Pathogenesis of crystal-induced inflammation.

Authors:  R C Landis; D O Haskard
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592

8.  Colchicine disposition in patients with familial Mediterranean fever with renal impairment.

Authors:  E Ben-Chetrit; J M Scherrmann; E Zylber-Katz; M Levy
Journal:  J Rheumatol       Date:  1994-04       Impact factor: 4.666

9.  Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B.

Authors:  E Gillespie; L M Lichtenstein
Journal:  J Clin Invest       Date:  1972-11       Impact factor: 14.808

10.  Colchicine in acute gout. Reassessment of risks and benefits.

Authors:  W N Roberts; M H Liang; S H Stern
Journal:  JAMA       Date:  1987-04-10       Impact factor: 56.272
View more
  45 in total

1.  Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

Authors:  Daria B Crittenden; R Aaron Lehmann; Laura Schneck; Robert T Keenan; Binita Shah; Jeffrey D Greenberg; Bruce N Cronstein; Steven P Sedlis; Michael H Pillinger
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

2.  Microplate spectrophotometry for high-throughput screening of cytotoxic molecules.

Authors:  C Tomelleri; C Dalla Pellegrina; R Chignola
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

Review 3.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

4.  Serum-soluble selectin levels in patients with Behçet's disease.

Authors:  Aşkin Ateş; Olcay Aydintuğ Tiryaki; Umit Olmez; Hüseyin Tutkak
Journal:  Clin Rheumatol       Date:  2007-01-06       Impact factor: 2.980

Review 5.  Autoinflammation: translating mechanism to therapy.

Authors:  Taylor A Doherty; Susannah D Brydges; Hal M Hoffman
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

Review 6.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

7.  Evaluation of circulating endothelial biomarkers in familial Mediterranean fever.

Authors:  Baris Onder Pamuk; Ismail Sari; Sema Selcuk; Goksel Gokce; Didem Leyla Kozaci
Journal:  Rheumatol Int       Date:  2013-01-29       Impact factor: 2.631

8.  Latest evidence on gout management: what the clinician needs to know.

Authors:  Christopher M Burns; Robert L Wortmann
Journal:  Ther Adv Chronic Dis       Date:  2012-11       Impact factor: 5.091

Review 9.  Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field.

Authors:  Robert L Wortmann
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 10.  Colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Peter L Thompson
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.